Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in the field of personalised medicine.
Using a microfluidic device that fits in the palm of your hand, scientists screened over 1100 treatment conditions (56 drug combinations x 20 replicates) on patient tumour cells. In the future, such tests could be used to inform clinicians on safe and effective combinations of cancer treatments. This research, incorporating fundamental science alongside clinical expertise at Aachen University Hospital, was led by EMBL group leader Christoph Merten and Julio Saez-Rodriguez, former group leader at EMBL-EBI and now Professor at Heidelberg University.
Small biopsies, many drugs
Directly testing multiple cancer drugs on biopsies – parts of the tumour which have been taken from a patient – is a powerful way to discover which drugs work best, and for whom. This is because depending on the specific tumour characteristics, cancer therapies can be more effective in some people than others. However, large-scale patient specific drug screenings have so far been limited by the small biopsy size that can typically be obtained from patients. That is why in the current paper, the team developed a miniaturised device which can test more drugs on a limited number of cells.
The research team initially tested 56 drug combinations on two different human cancer cell types grown in the lab. Drug combinations which killed both types of cancer cells were thought to be potentially toxic and thus unsafe for further testing. However, some drug combinations which targeted and killed only one type of cancer cell were found to be more effective than standard clinical therapies which only use one drug. These results were highly reproducible and could be validated in mouse models of human cancer.
Subsequently, cells from four cancer patient biopsies were applied to the microfluidic device and different drug combinations were tested. “We found that each individual cancer responded best to a different combination of drugs, highlighting the urgent need for patient-specific therapies,” says Federica Eduati, joint first author on the paper alongside Ramesh Utharala who designed and developed the microfluidic device.
“Before we transfer this technology into the clinics, we need to repeat these experiments in larger-scale mouse studies to understand which types of cancer this technology works best in,” says Christoph Merten. “Still, this is an exciting ‘proof of principle’ collaboration between scientists and clinicians, and we have shown that these tests can be run quickly and for less than $150 USD per patient.”
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Personalized Medicine Progressing in Premenopausal Breast Cancer on April 17, 2019 at 8:14 am
Eight-year follow-up findings from the TEXT and SOFT trials provided considerable insight into the use of adjuvant endocrine therapy for women with premenopausal hormone receptor (HR)–positive breast ... […]
- Leukemia Protein Atlas Holds Power to Accelerate Precision Medicine on April 17, 2019 at 7:15 am
The new protein classifications will help researchers and clinicians recommend better treatment and personalized medicine for patients suffering from this aggressive cancer, which occurs in the blood ... […]
- Personalized Medicine Market Size 2019 Production, Value, Supply and Demand Forecast 2024 on April 17, 2019 at 3:08 am
Apr 17, 2019 (Heraldkeeper via COMTEX) -- This research report based on ‘ Personalized Medicine market’ and available with Market Study Report, LLC, includes latest and upcoming industry trends in ... […]
- Computational researchers and oncologists develop protein cancer atlas to accelerate personalized medicine for leukemia patients on April 17, 2019 at 1:08 am
(April 17, 2019) -- Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis. To improve that survival rate, researchers at UTSA and ... […]
- Genomic Assays Advance Personalized Care in Early-Stage Breast Cancer on April 16, 2019 at 9:05 am
HR-positive/HER2-negative breast cancer and shed light on the overall outlook of personalized medicine in this setting. Chavez Mac Gregor: The data that were presented from the TAILORx trial at the ... […]
- Stanford, Notable Labs and Tempus collaborate on personalized medicine research for blood cancer on April 15, 2019 at 10:22 am
The future of personalized cancer treatments will be enabled by technology to understand the genetic variants of a person’s disease, as well as tools to determine the best treatment pathways for ... […]
- A Mathematical Representation of Precision Medicine on April 12, 2019 at 12:00 pm
This model unifies major concepts in epidemiology, population health and personalized medicine, a major step forward for precision health. […]
- Viewpoint: DNA data ‘rat race’ bringing down costs of precision medicine but perils of security risks escalate on April 12, 2019 at 9:44 am
There is no doubt that genetic testing brings opportunities to unlock the value in precision medicine. The hope is that personalized medicine which is targeted and effective will become cheaper. […]
- Centene pledges up to $100M to fund personalized medicine initiative at Washington University on April 8, 2019 at 12:21 pm
St. Louis, Missouri-based insurer Centene said it will fund up to $100 million in research at the Washington University School of Medicine to accelerate personalized treatments for conditions like ... […]
via Bing News